Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Cash & Current Investments (2016 - 2025)

Rein Therapeutics filings provide 10 years of Cash & Current Investments readings, the most recent being $3.2 million for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Current Investments fell 75.01% year-over-year to $3.2 million, compared with a TTM value of $3.2 million through Dec 2025, down 75.01%, and an annual FY2025 reading of $3.2 million, down 75.01% over the prior year.
  • Cash & Current Investments hit $3.2 million in Q4 2025 for Rein Therapeutics, down from $4.0 million in the prior quarter.
  • The five-year high for Cash & Current Investments was $52.2 million in Q3 2021, with the low at $3.2 million in Q4 2025.
  • Median Cash & Current Investments over the past 5 years was $12.5 million (2023), compared with a mean of $15.7 million.
  • The sharpest move saw Cash & Current Investments surged 485.99% in 2022, then crashed 79.49% in 2023.
  • Year by year, Cash & Current Investments stood at $3.6 million in 2021, then skyrocketed by 485.99% to $21.2 million in 2022, then decreased by 18.26% to $17.4 million in 2023, then dropped by 25.91% to $12.9 million in 2024, then plummeted by 75.01% to $3.2 million in 2025.
  • According to Business Quant data, Cash & Current Investments over the past three periods came in at $3.2 million, $4.0 million, and $5.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.